BL
BLFS
—
Nasdaq
Integrated Oil & Gas
Biolife Solutions Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,6B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
0,3 %
Net margin
—
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$29,98
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
BioLife Solutions Inc. is a biopreservation media manufacturer that generates revenue through the sale of specialized biological products, though its classification as an Integrated Oil & Gas company appears to be a data anomaly given its operational description and segment disclosures.
Business. BIOLIFE SOLUTIONS INC (BLFS) is an integrated oil and gas company that generates revenue through the sale of products. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic mix are not provided in the available data.
Classification66 %
SectorEnergy
Business sectorOil & Gas
IndustryIntegrated Oil & Gas
Generated · model-assisted
Sell-side consensus
HOLD9 analysts
3 buy6 hold0 sell
Avg 12m price target31,25
Analyst recommendations
9 analysts · consensus HoldBuy3
Hold6
Sell0
12-month price target
31,25
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
9 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
0,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy · THIS SECTOR+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to BLFS. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Peers
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated · BP (BP)
- EarningsQ3 2026 earnings (expected)2026-10-30 · estimated · Chevron (CVX)
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
BIOLIFE SOLUTIONS INC (BLFS) is an integrated oil and gas company that generates revenue through the sale of products. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic mix are not provided in the available data.
Classification66 %
SectorEnergy
Business sectorOil & Gas
IndustryIntegrated Oil & Gas
AI synthesis
GENERATEDBioLife Solutions maintains a conservative capital structure with $22.8 million in cash and equivalents against $2.5 million in short-term debt and zero long-term debt, resulting in a debt-to-equity ratio of 0.01 and a current ratio of 7.3. The company holds $372.2 million in total equity against $28.7 million in total liabilities, indicating strong balance sheet liquidity despite negative operating cash flow of -$0.5 million and free cash flow of -$0.7 million in Q1 2026. The low leverage profile supports the "low" liquidity risk assessment, although the negative cash conversion highlights operational cash burn.
Profitability metrics are exceptionally thin, with a return on equity of 0.32% and return on assets of 0.30%, reflecting minimal earnings generation relative to the asset base. The company reported net income of $1.2 million on gross profit of $17.5 million, but operating income was only $27,000, indicating high operating expense pressure. Valuation multiples are elevated, with a P/E ratio of 1,244.9 and an EV/EBITDA of 3,631.3, suggesting the market is pricing in significant future growth or that current earnings are not representative of normalized operations. The price-to-book ratio of 9.24 further underscores the premium valuation relative to tangible assets.
Key takeaways
- BioLife Solutions has a strong balance sheet with $22.8M in cash and no long-term debt, but negative free cash flow of -$0.7M in Q1 2026 indicates operational cash burn.
- Profitability is extremely thin with ROE of 0.32% and operating income of only $27K, leading to elevated valuation multiples (P/E 1,244.9).
- The company’s classification as Integrated Oil & Gas is likely erroneous given its biopreservation media operations, creating a mismatch in industry context.
- Historical material weaknesses in internal controls have been remediated, but residual risk remains if controls are not maintained effectively.
- Analyst sentiment is neutral-to-positive with a mean price target of $31.25, slightly above the current price of $29.98, ahead of Q2 2025 earnings.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income $27.0k.
Revenue—
Operating income$27.0k
Net income$1.2M
Free cash flow-$658.0k
EPS—
Operating cash flow-$491.0k
Financials
Income statement
Revenue—
Gross profit$17.5M
Operating income$27.0k
Net income$1.2M
Balance sheet
Total assets$400.9M
Total liabilities$28.7M
Total equity$372.2M
Cash & equivalents$22.8M
Long-term debt—
Cash flow
Operating cash flow-$491.0k
CapEx$167.0k
Free cash flow-$658.0k
SBC$4.8M
Highlights
- ▍Operating income $27.0k
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Operating income -$17.9M.
Revenue—
Operating income-$17.9M
Net income-$15.7M
Free cash flow—
EPS—
Operating cash flow$15.2M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$17.9M
Net income-$15.7M
Balance sheet
Total assets$392.1M
Total liabilities$38.3M
Total equity$353.7M
Cash & equivalents$29.5M
Long-term debt$0.00
Cash flow
Operating cash flow$15.2M
CapEx—
Free cash flow—
SBC$15.9M
Highlights
- ▍Operating income -$17.9M
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Operating income -$17.9M.
Revenue—
Operating income-$17.9M
Net income-$16.3M
Free cash flow—
EPS—
Operating cash flow$9.1M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$17.9M
Net income-$16.3M
Balance sheet
Total assets$387.2M
Total liabilities$40.1M
Total equity$347.2M
Cash & equivalents$31.9M
Long-term debt$0.00
Cash flow
Operating cash flow$9.1M
CapEx—
Free cash flow—
SBC$10.0M
Highlights
- ▍Operating income -$17.9M
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Operating income -$16.6M.
Revenue—
Operating income-$16.6M
Net income-$4.6M
Free cash flow$10.6M
EPS—
Operating cash flow$20.1M
Financials
Income statement
Revenue—
Gross profit$62.1M
Operating income-$16.6M
Net income-$4.6M
Balance sheet
Total assets$405.9M
Total liabilities$34.0M
Total equity$371.9M
Cash & equivalents$33.0M
Long-term debt$0.00
Cash flow
Operating cash flow$20.1M
CapEx$9.5M
Free cash flow$10.6M
SBC$23.0M
Highlights
- ▍Operating income -$16.6M
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Operating income -$4.5M.
Revenue—
Operating income-$4.5M
Net income-$20.2M
Free cash flow$5.2M
EPS—
Operating cash flow$8.4M
Financials
Income statement
Revenue—
Gross profit$50.1M
Operating income-$4.5M
Net income-$20.2M
Balance sheet
Total assets$399.5M
Total liabilities$50.6M
Total equity$348.9M
Cash & equivalents$91.5M
Long-term debt$5.0M
Cash flow
Operating cash flow$8.4M
CapEx$3.2M
Free cash flow$5.2M
SBC$30.9M
Highlights
- ▍Operating income -$4.5M
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income -$7.1M.
Revenue—
Operating income-$7.1M
Net income-$20.2M
Free cash flow$5.2M
EPS—
Operating cash flow$8.4M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$7.1M
Net income-$20.2M
Balance sheet
Total assets$399.5M
Total liabilities$50.6M
Total equity$348.9M
Cash & equivalents$95.4M
Long-term debt$5.0M
Cash flow
Operating cash flow$8.4M
CapEx$3.2M
Free cash flow$5.2M
SBC$30.9M
Highlights
- ▍Operating income -$7.1M
ANNUALFiled 2023-12-31
FY 2025 · Full-year highlights
Operating income -$17.2M.
Revenue—
Operating income-$17.2M
Net income-$68.0M
Free cash flow-$18.9M
EPS—
Operating cash flow-$12.5M
Financials
Income statement
Revenue—
Gross profit$41.3M
Operating income-$17.2M
Net income-$68.0M
Balance sheet
Total assets—
Total liabilities—
Total equity$337.7M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow-$12.5M
CapEx$6.4M
Free cash flow-$18.9M
SBC$33.2M
Highlights
- ▍Operating income -$17.2M
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Operating income -$70.8M.
Revenue—
Operating income-$70.8M
Net income-$66.4M
Free cash flow-$18.9M
EPS—
Operating cash flow-$12.5M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$70.8M
Net income-$66.4M
Balance sheet
Total assets$412.7M
Total liabilities$75.1M
Total equity$337.7M
Cash & equivalents$35.4M
Long-term debt$18.3M
Cash flow
Operating cash flow-$12.5M
CapEx$6.4M
Free cash flow-$18.9M
SBC$31.7M
Highlights
- ▍Operating income -$70.8M
Valuation FY
Market price
$32,15
Market cap
$1.48B
Enterprise valueⓘ
$1.46B
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
9.2x
P / Tangible bookⓘ
9.2x
Tangible book
$159.7M
Net cashⓘ
$20.3M
Current ratioⓘ
7.3
Debt / equityⓘ
0.0
ROAⓘ
0.3%
ROEⓘ
0.3%
Cash conversionⓘ
-41.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.9%
Revenue by segment
Business relationships
Business relationships4 disclosed relationships · 2 types · extracted from filings & disclosures
Customers2
Subsidiaries2
EX21:2d18f3cf0d28EX21:2d18f3cf0d28Subsidiarie97%
EX21:d070de61f4a6EX21:d070de61f4a6Subsidiarie97%
Supply chain
Vendors → BLFS ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 33 %
EPS
Consensus EPS
0,17
Predicted surprise
-0,03
Beat probability
33 %
Analysts
9
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-27 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,17 |
| Revenue | —no estimate | —no estimate | 114,0M USD |
| Operating income | —no estimate | —no estimate | 4,5M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy1
Buy2
Hold6
Sell0
Strong sell0
12-month price target$31,25 · Median $31,00
Low $30,00High $33,00
Operating income · consensus4,5M USD
EPS surprise
−159,4 %
reported vs consensus · miss
Revenue surprise
−15,6 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$30,00
Mean$31,25
Median$31,00
High$33,00
Spot$32,15
−2.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE0,3 %Bottom quartile
D/E0,01Above P75
Cash Conv-0,41Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- BIOLIFE SOLUTIONS INC company facts · 2026-07-27
- BIOLIFE SOLUTIONS INC 10-Q 2026-05-07 · 2026-07-27
- BIOLIFE SOLUTIONS INC 10-K 2026-02-26 · 2026-07-27
- BIOLIFE SOLUTIONS INC 10-Q 2025-11-06 · 2026-07-27
- BIOLIFE SOLUTIONS INC 10-Q 2025-08-07 · 2026-07-27
- pre_earnings_window (pre_earnings_window) on BLFS · 2026-07-27
- BioLife Solutions Inc Market data — analyst estimates · 2026-07-27
- BioLife Solutions Inc Market data — ESG · 2026-07-27
- BIOLIFE SOLUTIONS INC HA canonical relationships · 2026-07-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,09 %$0M
- Institutional Investor · as of 2026-03-310,01 %$23M
- Funds · as of 2026-03-310,01 %$45M
- Investment Managers · as of 2026-03-310,00 %$20M
- Institutional Investor · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2024-06-300,00 %$118M
- Brokerage Firms · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$28M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2025-12-310,00 %$75M
- Investment Managers · as of 2026-03-310,00 %$30M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2024-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$8M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 10 sellsnet -$30,2M8 insiders · last 365d
- Chief Technology Officer · Common StockOther 275 @ $29,15$8K · 2026-07-17
- Chief Financial Officer · Common StockOther 844 @ $27,79$23K · 2026-07-07
- Chief Marketing Officer · Common StockOther 293 @ $27,79$8K · 2026-07-07
- EVP & Chief Scientific Officer · Common StockOther 516 @ $27,79$14K · 2026-07-07
- Director, President and CEO · Common StockOther 2 775 @ $26,04$72K · 2026-06-18
- EVP & Chief Scientific Officer · Common StockOther 564 @ $26,04$15K · 2026-06-18
- Chief Marketing Officer · Common StockOther 470 @ $26,04$12K · 2026-06-18
- Chief Technology Officer · Common StockOther 420 @ $26,04$11K · 2026-06-18
- Chief Financial Officer · Common StockOther 937 @ $26,04$24K · 2026-06-18
- Chief Marketing Officer · Common StockOther 356 @ $26,10$9K · 2026-06-08
- Chief Financial Officer · Common StockOther 1 026 @ $26,10$27K · 2026-06-08
- EVP & Chief Scientific Officer · Common StockOther 627 @ $26,10$16K · 2026-06-08
- 10% owner · Common Stock, par value $0.001 per shareSold 650 000 @ $23,70$15,4M · 2026-05-21
- 10% owner · Common Stock, par value $0.001 per shareSold 250 000 @ $23,70$5,9M · 2026-05-20
- 10% owner · Common Stock, par value $0.001 per shareSold 300 000 @ $22,65$6,8M · 2026-05-19
- EVP & Chief Scientific Officer · Common StockOther 515 @ $19,27$10K · 2026-04-08
- Chief Financial Officer · Common StockOther 844 @ $19,27$16K · 2026-04-08
- Chief Marketing Officer · Common StockOther 293 @ $19,27$6K · 2026-04-08
- Chief Quality and Operations · Common StockSold 2 577 @ $19,17$49K · 2026-03-23
- Director, President and CEO · Common StockOther 11 101 @ $19,12$212K · 2026-03-19
- Chief Marketing Officer · Common StockOther 1 879 @ $19,12$36K · 2026-03-19
- Chief Technology Officer · Common StockOther 1 681 @ $19,12$32K · 2026-03-19
- Chief Financial Officer · Common StockOther 3 749 @ $19,12$72K · 2026-03-19
- Chief Human Resources Officer · Common StockOther 931 @ $19,12$18K · 2026-03-19
- EVP & Chief Scientific Officer · Common StockOther 2 255 @ $19,12$43K · 2026-03-19
Short positioning
2.9Mshares short-5.2% vs prior
4.97days to cover
37.9%short of daily vol
84fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
BLFSCanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companyPeerSectorCustomersSubsidiaries
Evidence & claims
From filings & derived data- Current liabilities (annual): USD 22.98MUnknown
- Long-term debt (annual): USD 5MUnknown
- Total assets (annual): USD 405.88MUnknown
- Cash & equivalents (annual): USD 33.04MUnknown
- Capex (annual): USD 9.48MUnknown
- Cost of revenue (annual): USD 34.1MUnknown
- Shareholders' equity (annual): USD 371.89MUnknown
- Current assets (annual): USD 136.56MUnknown
- Net income (annual): USD -4.59MUnknown
- Total liabilities (annual): USD 34MUnknown
- Operating income (annual): USD -16.6MUnknown
- Shares outstanding (annual): 48.2MUnknown
- Gross profit (annual): USD 62.12MUnknown
- Operating cash flow (annual): USD 20.11MUnknown
- Pre-tax income (annual): USD -12.08MUnknown
- EPS (basic) (annual): USD-PER-SHARES -0Unknown
- EPS (diluted) (annual): USD-PER-SHARES -0Unknown
- R&D expense (annual): USD 7.57MUnknown
- Operating income (annual): USD -4.48MUnknown
- Net income (annual): USD -20.18MUnknown
- Cost of revenue (annual): USD 24.55MUnknown
- Current assets (annual): USD 148.76MUnknown
- Operating cash flow (annual): USD 8.43MUnknown
- Total assets (annual): USD 399.49MUnknown
Showing 24 of 34 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-28EVENTQ2 2025 earnings (confirmed · filed)
2026-07-27 07:40 UTCEVENTEarnings Window
2026-07-17INSIDERWerner Sean transacted 275 sh — Chief Technology Officer ~$8k
2026-07-07INSIDERBerard Todd transacted 293 sh — Chief Marketing Officer ~$8k
2026-07-07INSIDERWichterman Troy transacted 844 sh — Chief Financial Officer ~$23k
2026-07-07INSIDERMathew Aby J. transacted 516 sh — EVP & Chief Scientific Officer ~$14k
2026-06-18 00:00 UTCINSIDER8 insider transactions — 2026-06 · net sell $187k
2026-06-18INSIDERDE GREEF RODERICK transacted 2.8k sh — Director, President and CEO ~$72k
2026-06-18INSIDERMathew Aby J. transacted 564 sh — EVP & Chief Scientific Officer ~$15k
2026-06-18INSIDERBerard Todd transacted 470 sh — Chief Marketing Officer ~$12k
2026-06-18INSIDERWerner Sean transacted 420 sh — Chief Technology Officer ~$11k
2026-06-18INSIDERWichterman Troy transacted 937 sh — Chief Financial Officer ~$24k
2026-06-08INSIDERBerard Todd transacted 356 sh — Chief Marketing Officer ~$9k
2026-06-08INSIDERWichterman Troy transacted 1.0k sh — Chief Financial Officer ~$27k
2026-06-08INSIDERMathew Aby J. transacted 627 sh — EVP & Chief Scientific Officer ~$16k
2026-05-21 00:00 UTCINSIDER3 insider transactions — 2026-05 · net sell $28.1M
2026-05-21INSIDERCasdin Partners Master Fund, L.P. sold 650.0k sh Common Stock, par value $0.001 per share — 10% owner ~$15.40M
2026-05-20INSIDERCasdin Partners Master Fund, L.P. sold 250.0k sh Common Stock, par value $0.001 per share — 10% owner ~$5.92M
2026-05-19INSIDERCasdin Partners Master Fund, L.P. sold 300.0k sh Common Stock, par value $0.001 per share — 10% owner ~$6.79M
2026-04-08 00:00 UTCINSIDER3 insider transactions — 2026-04
2026-04-08INSIDERMathew Aby J. transacted 515 sh — EVP & Chief Scientific Officer ~$10k
2026-04-08INSIDERWichterman Troy transacted 844 sh — Chief Financial Officer ~$16k
2026-04-08INSIDERBerard Todd transacted 293 sh — Chief Marketing Officer ~$6k
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD 1.2M
2026-03-23 00:00 UTCINSIDER14 insider transactions — 2026-03 · net sell $2.5M
2026-03-23INSIDERFoster Karen A. sold 2.6k sh — Chief Quality and Operations ~$49k
2026-03-19INSIDERDE GREEF RODERICK transacted 11.1k sh — Director, President and CEO ~$212k
2026-03-19INSIDERBerard Todd transacted 1.9k sh — Chief Marketing Officer ~$36k
2026-03-19INSIDERWerner Sean transacted 1.7k sh — Chief Technology Officer ~$32k
2026-03-19INSIDERWichterman Troy transacted 3.7k sh — Chief Financial Officer ~$72k
2026-03-19INSIDERAebersold Sarah transacted 931 sh — Chief Human Resources Officer ~$18k
2026-03-19INSIDERMathew Aby J. transacted 2.3k sh — EVP & Chief Scientific Officer ~$43k
Showing the 40 most recent of 51 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage